@article{48ea6019a1c04b6e98044f216af6e9d1,
title = "MAFG is a Transcriptional Repressor of Bile Acid Synthesis and Metabolism",
abstract = "Summary Specific bile acids are potent signaling molecules that modulate metabolic pathways affecting lipid, glucose and bile acid homeostasis, and the microbiota. Bile acids are synthesized from cholesterol in the liver, and the key enzymes involved in bile acid synthesis (Cyp7a1, Cyp8b1) are regulated transcriptionally by the nuclear receptor FXR. We have identified an FXR-regulated pathway upstream of a transcriptional repressor that controls multiple bile acid metabolism genes. We identify MafG as an FXR target gene and show that hepatic MAFG overexpression represses genes of the bile acid synthetic pathway and modifies the biliary bile acid composition. In contrast, loss-of-function studies using MafG+/- mice causes de-repression of the same genes with concordant changes in biliary bile acid levels. Finally, we identify functional MafG response elements in bile acid metabolism genes using ChIP-seq analysis. Our studies identify a molecular mechanism for the complex feedback regulation of bile acid synthesis controlled by FXR.",
author = "{De Aguiar Vallim}, {Thomas Q.} and Tarling, {Elizabeth J.} and Hannah Ahn and Hagey, {Lee R.} and Romanoski, {Casey E.} and Lee, {Richard G.} and Graham, {Mark J.} and Hozumi Motohashi and Masayuki Yamamoto and Edwards, {Peter A.}",
note = "Funding Information: We thank Drs. Timothy Willson and David Deaton for the kind gift of GSK2324 and Peter Tontonoz and his lab for helpful discussions. We also thank Tieyan Han, Joan Cheng, Christina Cheung, and Elizabeth Nam for excellent technical assistance. This work was supported in part by United States Public Health Service, grants 1R01DK102559-01 and the Laubish fund at UCLA (to P.A.E.); American Heart Association (AHA) Beginning Grant In Aid (13BGIA17080038) and NIH K99HL118161 (to E.J.T); and AHA Postdoctoral Fellowship (12POST11760017) and NIH NHLBI K99HL12348501 (to C.E.R.). T.Q.d.A.V. was supported by an AHA Scientist Development Grant (14SDG18440015), University of California Los Angeles (UCLA) Clinical and Translational Science Institute (CTSI) grant (UL1TR000124), a UCLA Center for Ulcer Research and Education (CURE):Digestive Diseases Research Center (DDRC) grant (DK41301), and a UCLA Diabetes Research Center (DRC) grant (DK063491). R.G. Lee and M.J. Graham are employees and shareholders of Isis Pharmaceuticals. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",
year = "2015",
month = feb,
day = "3",
doi = "10.1016/j.cmet.2015.01.007",
language = "English",
volume = "21",
pages = "298--311",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "2",
}